BRIEF-Merck’S Tulisokibart Met Primary And Key Secondary Endpoints In The Phase 3 Atlas-Uc Induction-Only Study In Patients With Moderately To Severely Active Ulcerative Colitis (Uc)

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00

June 22 (Reuters) - Merck & Co Inc MRK.N:

  • MERCK’S TULISOKIBART MET PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 ATLAS-UC INDUCTION-ONLY STUDY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)

  • MERCK CO - NO SAFETY CONCERNS IDENTIFIED IN PHASE 3 ATLAS-UC STUDY OF TULISOKIBART

  • MERCK’S TULISOKIBART MET PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 ATLAS-UC INDUCTION-ONLY STUDY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)

  • MERCK CO - TULISOKIBART FIRST ANTI-TL1A ANTIBODY TO SHOW CLINICAL REMISSION AT 12 WEEKS IN PHASE 3 UC TRIAL

Source text: ID:nBw6c8dfca

Further company coverage: MRK.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.